USP12 can inhibit NF-κB signaling activity to regulate the production of chemokines (such as CXCL8 and CXCL1), which then modulate the tumor immune microenvironment to alter the response of NSCLC to immunotherapy [66]. This evidence concerns the gene CXCL1 and non-small cell lung carcinoma.